Everything below concerns Chain of custody. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or inert plastic | Compatibility depends on peptide and solvent |
| Headspace gas | Nitrogen or argon | Used to limit oxygen exposure |
| Common reconstitution solvent | Water or buffered aqueous solution | Organic co-solvents may be needed for hydrophobic peptides |
| Freeze-thaw stability | Varies by peptide | Aliquoting reduces repeated cycles |
| Documentation | Lot, date, concentration, storage location | Supports traceability and reproducibility |
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
== Medical uses == As of 2022, across the European countries where etifoxine has been approved (including France, Luxembourg, Malta, Romania and Bulgaria), the main approved indication is for the treatment of the psychosomatic manifestations of anxiety. When etifoxine was first approved in France in 1979, the original indication was for the treatment of "psychosomatic manifestations of anxiety, for instance autonomic dystonia, particularly with cardiovascular expression". Over time, the indication for etifoxine has been more formalized as the treatment of adjustment disorder (situational depression) with anxiety (ADWA) (for example, stress-related anxiety). Etifoxine has been found to reduce scores on the Hamilton Anxiety Rating Scale (HAM‑A) in people with adjustment disorder with anxiety by approximately 50 to 75% after 4 weeks of treatment in clinical trials (as per the AMETIS, ETILOR, ETIZAL, STRETI studies). The medication is similarly effective or more effective than benzodiazepines like lorazepam, alprazolam, and clonazepam and more effective than buspirone for adjustment disorder with anxiety on the basis of directly comparative randomized controlled trials. However, in the AMETIS study, both etifoxine and lorazepam failed to show greater effectiveness over placebo. In the trials comparing etifoxine to clonazepam, lorazepam, and alprazolam, total daily doses of the benzodiazepines were limited to their maintenance daily dose, set at 1 mg clonazepam, 2 mg lorazepam, and 1.5 mg alprazolam, divided across 3 doses per day.
== Formation == A glucuronosyltransferase enzyme UGT2B7 present in human liver converts codeine to its glucuronide by adding a sugar acid at the hydroxy group, with uridine diphosphate (UDP) as byproduct:
=== Characteristics === Unintentional weight loss may result from loss of body fats, loss of body fluids, muscle atrophy, or a combination of these. It is generally regarded as a medical problem when at least 10% of a person's body weight has been lost in six months or 5% in the last month. Another criterion used for assessing weight that is too low is the body mass index (BMI). However, even lesser amounts of weight loss can be a cause for serious concern in a frail elderly person. Unintentional weight loss can occur because of an inadequately nutritious diet relative to a person's energy needs (generally called malnutrition). Disease processes, changes in metabolism, hormonal changes, medications or other treatments, disease- or treatment-related dietary changes, or reduced appetite associated with a disease or treatment can also cause unintentional weight loss. Poor nutrient utilization can lead to weight loss, and can be caused by fistulae in the gastrointestinal tract, diarrhea, drug-nutrient interaction, enzyme depletion and muscle atrophy. Continuing weight loss may deteriorate into wasting, a vaguely defined condition called cachexia. Cachexia differs from starvation in part because it involves a systemic inflammatory response. It is associated with poorer outcomes. In the advanced stages of progressive disease, metabolism can change so that they lose weight even when they are getting what is normally regarded as adequate nutrition and the body cannot compensate.
==== Elimination ==== The elimination of trazodone is biphasic: the first phase's half-life (distribution) is 3 to 6 hours, and the following phase's half-life (elimination) is 4.1 to 14.6 hours. The elimination half-life of extended-release trazodone is 9.1 to 13.2 hours. The elimination half-life of mCPP is 2.6 to 16.0 hours and is longer than that of trazodone. Metabolites are conjugated to gluconic acid or glutathione and around 70 to 75% of 14C-labelled trazodone was found to be excreted in the urine within 72 hours. The remaining drug and its metabolites are excreted in the faeces via biliary elimination. Less than 1% of the drug is excreted in its unchanged form. After an oral dose of trazodone, it was found to be excreted 20% in the urine as TPA and conjugates, 9% as the dihydrodiol metabolite, and less than 1% as unconjugated mCPP. mCPP is glucuronidated and sulfated similarly to other trazodone metabolites.
Sources: en.wikipedia.org
The company is working with food supplier Warabeya Nichiyo, which already supplies 7-Eleven's commissary food offerings in Japan, to create a US supply chain that will bring higher-quality Western and Japanese food offerings to 7-Eleven stores. Isaka also announced 7-Eleven's plan to grow its footprint and consolidate a larger portion of the US convenience store market. The company announced plans to add hot and cold food options and a larger baked goods selection at up to 1,600 Speedway and Stripes stores. Fuel In the U.S., many 7-Eleven filling stations had gasoline distributed by Citgo, which in 1983 were purchased by Southland Corporation. 50% of Citgo was sold in 1986 to Petróleos de Venezuela, S.A., and the remaining 50% was acquired in 1990. Although Citgo was the predominant partner of 7-Eleven, other oil companies are also co-branded with 7-Eleven, including Fina, Exxon, Mobil, Gulf, Marathon, BP, Amoco, Phillips 66, Conoco, 76, Shell, Chevron (some former TETCO convenience stores were co-branded with Chevron, and Texaco prior to the 7-Eleven purchase in late 2012), Sunoco, and Sinclair. Conoco is the largest 7-Eleven licensee in North America. The Pittsburgh market alone—where 7-Eleven is the market leader by store count but third behind Sheetz and GetGo in revenue— offers fuel from Exxon, Gulf, Marathon (both legacy 7-Eleven locations and Speedway), BP, and Sunoco (the latter two being from 7-Eleven's acquisitions of their company-owned-and-operated locations in the area) and also having previously offered Citgo and Pennzoil at some locations.
In historical fungarium material, contamination can be especially severe because specimens were often stored in close contact on paper sheets or in herbarium packets, increasing the likelihood of cross-contamination, while universal fungal barcode primers may amplify contaminant fungi alongside the target specimen. High-throughput sequencing is better suited to such degraded material. In 2012, researchers reported successful ITS sequencing from a lichen herbarium specimen collected in 1859, then the oldest sequenced fungal herbarium sample. A 2025 study showed that historical lichen specimens, including type material, could be used for whole genome sequencing, allowing genome-wide analysis of both the fungal and algal symbionts. High-throughput sequencing can also recover barcode data from very small amounts of historical material, reducing the need for destructive sampling of valuable specimens while allowing taxonomic re-evaluation of long-preserved collections. A modified metabarcoding approach using nested, barcoded primers has enabled the cost-effective sequencing of hundreds of specimens simultaneously. In one study, this approach produced ITS sequences for 762 out of 766 macrofungal specimens, with taxonomic identities derived from the sequence data achieving over 90 percent accuracy. Such methods have allowed previously unidentified or misidentified specimens to be recognized under newer taxonomic concepts.
The BMSS Medal is awarded by the British Mass Spectrometry Society to individuals who have worked in the United Kingdom and have made sustained contributions by individual members of the British Mass Spectrometry Society to the promotion and advancement of mass spectrometry, primarily within the UK.
Sources: en.wikipedia.org
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.
Aliquoting divides a solution into smaller portions so that each portion is handled once. This reduces repeated freeze-thaw cycles and limits contamination risk. It also makes it easier to track usage and maintain consistent test conditions.
Refreezing is possible for some peptides but can promote aggregation or precipitation. The effect depends on the peptide, solvent, concentration, and freezing rate. Many laboratory protocols therefore recommend single-use aliquots instead of repeated refreezing.
Allow the sealed vial to equilibrate to room temperature so condensation does not form on the powder or solution. Wipe the exterior with a suitable disinfectant if the workspace requires it. Open the vial in a clean, draft-free area to reduce contamination.